MB-07811

• Description :

  MB-07811 (VK-2809) is an orally active HepDirect prodrug of MB07344, a liver-targeted thyroid hormone receptor-β agonist[1]. MB-07811 has cholesterol and triglycerides lowering activity[2].

• Product Name Alternative :

  VK-2809

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Thyroid Hormone Receptor

• Type :

  Reference compound

• Related Pathways :

  Vitamin D Related/Nuclear Receptor

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Metabolic Disease; Endocrinology

• Assay Protocol :

  https://www.medchemexpress.com/mb-07811.html

• Purity :

  99.75

• Solubility :

  DMSO : 250 mg/mL (ultrasonic)

• Smiles :

  OC1=CC=C(CC2=C(C)C=C(OC[P@]3(OCC[C@@H](C4=CC=CC(Cl)=C4)O3)=O)C=C2C)C=C1C(C)C

• Molecular Formula :

  C28H32ClO5P

• Molecular Weight :

  514.98

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Cable EE, et al. Reduction of hepatic steatosis in rats and mice after treatment with aliver-targeted thyroidhormone receptor agonist. Hepatology. 2009 Feb;49 (2) :407-17.|[2]Erion MD, et al. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci U S A. 2007 Sep 25;104 (39) :15490-5.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• CAS Number :

  [852948-13-1]